Corvus Pharmaceuticals (CRVS) Receivables - Other (2021 - 2024)

Corvus Pharmaceuticals' Receivables - Other history runs 4 years deep, the most recent figure standing at $70000.0 for Q3 2024.

• On a quarterly basis, Receivables - Other changed N/A year-over-year to $70000.0 in Q3 2024; TTM through Sep 2024 was $70000.0, a N/A change from a year earlier, with the FY2023 full-year figure at $26000.0, down 95.58% from the prior year.
• Receivables - Other rose to $70000.0 in Q3 2024 per CRVS's latest filing, from $35000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $588000.0 in Q4 2022 and bottomed at $26000.0 in Q4 2023.
• The 4-year median for Receivables - Other is $373000.0 (2022), against an average of $291454.5.
• Across the five-year window, Receivables - Other soared 82.25% in 2022 and slumped 95.58% in 2023, its largest moves.
• Year by year, Receivables - Other stood at $507000.0 in 2021, then rose by 15.98% to $588000.0 in 2022, then slumped by 95.58% to $26000.0 in 2023, then surged by 169.23% to $70000.0 in 2024.
• Per Business Quant, the three latest CRVS Receivables - Other figures stand at $70000.0 (Q3 2024), $35000.0 (Q2 2024), and $26000.0 (Q1 2024).